Measures of inflammation (independent variables) and damage (dependent variables) at baseline, 3-, 6- and 12-month follow-up
| Baseline | 3 Months | 6 Months | 12 Months | |
|---|---|---|---|---|
| N=55 | N=54 | N=52 | N=51 | |
| 28-SJC | 6.0 (3.0–10.0) | 6.0 (2.8–9.3) | 4.0* (2.0–9.0) | 3.0* (0.0–6.0) |
| 28-TJC | 3.5 (1.0–11.0) | 3.0 (0.8–9.0) | 2.0* (0.0–9.0) | 2.0* (0.0–7.0) |
| DAS28 | 3.9 (2.9–4.8) | 3.8 (2.8–4.8) | 3.4* (2.4–4.8) | 3.3* (2.2–4.4) |
| ESR | 12.0 (8.0–20.0) | 11.0 (8.0–18.8) | 10.5 (7.0–19.5) | 11.0 (7.0–17.0) |
| CRP | 4.9 (1.9–7.8) | 2.8* (1.5–6.1) | 3.0 (1.2–8.5) | 2.9 (1.3–5.6) |
| MRI synovitis | 5.0 (3.0–6.0) | 4.5 (3.0–6.0) | 4.0* (3.0–5.0) | 4.0* (3.0–5.0) |
| MRI bone marrow oedema | 2.5 (1.0–4.0) | 2.0 (1.0–4.0) | 2.0 (1.0–4.0) | 2.0* (1.0–4.0) |
| MRI tenosynovitis | 9.0 (6.0–11.0) | 8.0* (6.3–9.8) | 8.0* (6.0–9.0) | 7.0* (5.0–9.0) |
| Total vdHSS | 4.0 (1.0–7.0) | 4.0† (1.0–9.0) | 4.0‡ (1.5–10.0) | 7.0§ (2.0–13.0) |
| MRI erosions | 8.0 (5.0–11.0) | 8.0 (6.0–11.0) | 9.0 (5.5–12.0) | 9.0 (5.5–12.0) |
Data are presented as median (IQR).
↵* p≤0.05 (Wilcoxon signed rank test).
↵† Total vdHSS at 6-month follow-up.
↵‡ Total vdhHSS at 12-month follow-up.
↵§ Total vdHSS at 36-month follow-up.
28-SJC, 28-swollen joint count; 28-TJC, 28-tender joint count; CRP, C reactive protein; DAS28, disease activity score based on 28 joint counts; ESR, erythrocyte sedimentation rate; vdHSS, van der Heijde Sharp score.